Consider drug efficacy before first-in-human trials

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nature

• Publication date

  2017-02-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/542025aPMID 28150789
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• First-in-Human Clinical Trials - What We Can Learn from Tragic Failures.

  2016cited by this paper
• Policy: Global standards for stem-cell research

  2016cited by this paper
• Risks of phase I research with healthy participants: A systematic review

  2016cited by this paper
• Assessing risk/benefit for trials using preclinical evidence: a proposal

  2015cited by this paper
• A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib

  2015cited by this paper
• Preclinical research: Make mouse studies work

  2014cited by this paper
• Replication and reproducibility in spinal cord injury research.

  2012cited by this paper
• Costs and benefits of the national cancer institute central institutional review board.

  2010cited by this paper
• Current status of neuroprotection for cerebral ischemia: synoptic overview.

  2009cited by this paper
• Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards.

  2008cited by this paper
• Stroke: Pathophysiology, Diagnosis, and Management, vols. 1 and 2

  1987cited by this paper

• Precision Is Not Enough: When Tools Outpace Translation in Ocular Gene Therapy

  2026cites this paper
• Challenges of Conducting Risk‐Benefit Analysis of Early Phase Clinical Trials: Results of a National Survey of IRB Chairs

  2025cites this paper
• Factors affecting drug delivery system translation: A focus on advanced technologies, biological barriers, and regulatory challenges.

  2025cites this paper
• Assessing risk of bias in toxicological studies in the era of artificial intelligence

  2025cites this paper
• The fundamental role of mitochondria–endoplasmic reticulum contacts in ageing and declining healthspan

  2025cites this paper
• Navigating First‐in‐Human and Early‐Phase Patient Studies: Study Designs, Risk Mitigation, and Population Selection Challenges

  2025cites this paper
• Identification of a Risk Signature and Immune Cell Infiltration Based on Extracellular Matrix-Related lncRNAs in Lung Adenocarcinoma.

  2025cites this paper
• Promising strategies in natural products treatments of psoriasis-update

  2024cites this paper
• Unveiling the fibrotic puzzle of endometriosis: An overlooked concern calling for prompt action

  2024cites this paper
• Digitalization of toxicology: improving preclinical to clinical translation

  2024cites this paper
• Animals in Respiratory Research

  2024cites this paper
• Healthy behavior between traditional and modern medicine

  2024cites this paper
• Targeting the Major Capsid Protein of Rock Bream Iridovirus by Trapa Natans Phytochemical Compounds; a Molecular Docking Approach

  2023cites this paper
• The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group Workshop: Translating Novel Discoveries to and from the Clinic.

  2023cites this paper
• Diversity and inclusion for rodents: how animal ethics committees can help improve translation

  2023cites this paper
• Era of the 4D animal model

  2023cites this paper
• Ethical Considerations for Phase I Trials in Oncology.

  2022cites this paper
• Preclinical efficacy in investigator's brochures: Stakeholders' views on measures to improve completeness and robustness

  2022cites this paper
• Potential of Drug Efficacy Evaluation in Lung and Kidney Cancer Models Using Organ-on-a-Chip Technology

  2021cites this paper
• Moving towards less biased research

  2021cites this paper
• Individualized therapy trials: navigating patient care, research goals and ethics

  2021cites this paper
• A New Ethical Framework for Assessing the Unique Challenges of Fetal Therapy Trials

  2021cites this paper
• Clinical Trials, Ethics, and Human Protections Policies

  2020cites this paper
• Clarifying how to deploy the public interest criterion in consent waivers for health data and tissue research

  2020cites this paper
• The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models

  2020cites this paper
• Toward standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function.

  2020cites this paper
• Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?

  2020cites this paper
• Do we really know how many clinical trials are conducted ethically? Why research ethics committee review practices need to be strengthened and initial steps we could take to strengthen them

  2020cites this paper
• Biocommunication of Phages

  2020cites this paper
• Levelling the Translational Gap for Animal to Human Efficacy Data

  2020cites this paper
• Endometriosis: current challenges in modeling a multifactorial disease of unknown etiology

  2020cites this paper
• Quantification of clinically applicable stimulation parameters for precision near-organ neuromodulation of human splenic nerves

  2020cites this paper
• Phage Therapy in Cystic Fibrosis. Challenges and Perspectives

  2020cites this paper
• Stem Cells in the Treatment of Neuropathic Pain: Research Progress of Mechanism

  2020cites this paper
• The ethics of innovation for Alzheimer’s disease: the risk of overstating evidence for metabolic enhancement protocols

  2020cites this paper
• 7. Seven Levels of Analogical Fallacies—From Mice to Women or from reductionist experiments in mice to functional transcriptomics in humans

  2020cites this paper
• Robust Preclinical Evidence in Somatic Cell Genome Editing: A Key Driver of Responsible and Efficient Therapeutic Innovations

  2020cites this paper
• Autophagy-Modulating Drugs in the SARS-CoV-2 War Open Questions for Harnessing

  2020cites this paper
• Rescuing Informed Consent: How the new “Key Information” and “Reasonable Person” Provisions in the Revised U.S. Common Rule open the door to long Overdue Informed Consent Disclosure Improvements and why we need to walk Through that door

  2019cites this paper
• Reply to ‘Correcting the ASCO position on phase I clinical trials in cancer’

  2019cites this paper
• Ex vivo toxicological evaluation of experimental anticancer gold(i) complexes with lansoprazole-type ligands.

  2019cites this paper
• The significant cost of systematic reviews and meta-analyses: A call for greater involvement of machine learning to assess the promise of clinical trials

  2019cites this paper
• Los comités de ética de investigación en América Latina: ¿Para qué sirven?

  2019cites this paper
• 3Rs missing: animal research without scientific value is unethical

  2019cites this paper
• How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence?

  2019cites this paper
• Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.

  2019cites this paper
• Applications of tumor chip technology.

  2018cites this paper
• Chapter 1 – Reproducibility in Biomedical Research

  2018cites this paper
• The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?

  2018cites this paper
• Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross‐sectional study

  2018cites this paper
• Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review

  2018cites this paper
• The bench is closer to the bedside than we think: Uncovering the ethical ties between preclinical researchers in translational neuroscience and patients in clinical trials

  2018cites this paper
• Preclinical efficacy studies in investigator brochures: Do they enable risk–benefit assessment?

  2018cites this paper
• Determining the Balance Between Drug Efficacy and Safety by the Network and Biological System Profile of Its Therapeutic Target

  2018cites this paper
• The Research Optimist's Defense

  2017cites this paper
• GLOBAL PHARMACEUTICAL SUPPLY CHAIN TRENDS

  2017cites this paper
• Organ on Chip in Development (ORCHID)

  2017cites this paper
• Live or let die: Neuroprotective and anti-cancer effects of nutraceutical antioxidants.

  2017cites this paper
• Development of novel anticancer agents for protein targets

  2017cites this paper
• Tissue chips - innovative tools for drug development and disease modeling.

  2017cites this paper
• Critical Issues for the Translation of Cardioprotection.

  2017cites this paper
• Gender bias: track revisions and appeals

  2017cites this paper